BJMO - 2022, issue Special, may 2022
A. Dekker MD, T. Feys MBA, MSc
About 15% of patients with localised prostate cancer (PCa) are identified as having a high risk for disease recurrence and these patients account for the vast majority of PCa deaths. To date, however, the optimal treatment for patients with high-risk, localized PCa remains controversial. While it is important to offer these patients an effective treatment, this treatment should not come with excessive side effects or impact the patient’s quality of life (QoL).1 During a session at the 2022 BMUC meeting, the different treatment options for these patients were discussed from the perspective of the surgeon, the medical oncologist and the radiation oncologist.
Read moreBJMO - 2022, issue Special, may 2022
A. Dekker MD, T. Feys MBA, MSc
What is the role of the patient in the management of prostate cancer? During BMUC 2022, André Deschamps, prostate cancer (PCa) patient and Chairman of Europa UOMO aimed to answer this question. In his lecture, he discussed the effect of PCa and its treatment on the daily life of patients and addressed some of the barriers and gaps that hamper a closer involvement of patients in the treatment decision process. 1
Read moreBJMO - 2021, issue Special, april 2021
A. Dekker MD, T. Feys MBA, MSc
A better understanding of critical molecular and cellular mechanisms driving tumor initiation, maintenance, and progression in non-small-cell lung cancer (NSCLC) has led to the discovery of a variety of novel drug targets and the development of new treatment strategies. Since the introduction of tyrosine kinase inhibitors (TKIs) targeting mutant EGFR, we have witnessed a continued shift towards a biomarker-driven treatment algorithm for patients with advanced-stage NSCLC. The identification of less common oncogene drivers led to a marked reshaping of the diagnostic and therapeutic approach towards NSCLC. The introduction of novel highly selective inhibitors is expanding the use of targeted therapies to rare and ultra-rare subsets of patients, further increasing the therapeutic armamentarium of advanced NSCLC. In this article we will briefly discuss the recent advances for the targeted treatment of advanced NSCLC patients with RET fusions, MET exon14 skipping, HER2 overexpression and KRAS mutations.
Read moreBJMO - 2021, issue Special, april 2021
A. Dekker MD, T. Feys MBA, MSc
The introduction of tyrosine kinase inhibitors (TKIs) targeting mutant epidermal growth factor receptor (EGFR) has revolutionized the treatment of patients with EGFR-mutant advanced NSCLC. In the recently published REVEAL trial, investigators assessed the current clinical practice for these patients in Belgium revealing some striking observations. In fact, one out of five EGFR-mutant advanced NSCLC patients in this study did not receive ESMO standard of care in first line. After progression on a first EGFR-TKI, Moreover, nearly 30% of patients were not tested for the presence of a T790M mutation after progression on first-line treatment with an EGFR TKI and a quarter of patients did not receive subsequent systemic treatment for NSCLC. These findings underscore the need for more diligent decision-making in the treatment of these patients in order to maximize the clinical potential of EGFR TKIs.
Read moreBJMO - 2021, issue Special, december 2021
A. Dekker MD, T. Feys MBA, MSc
We want you to be completely up to date on the results presented at SABCS 2020, hence this article will focus on three presentations that were not previously addressed in the congress highlights. A first presentation reported on the high rate of persistent controlled substance use following mastectomy with reconstruction surgery. Results of a large systematic review and meta-analysis provide solid evidence on the chance of pregnancy after breast cancer and underscores the importance of oncofertility counselling. A third interesting study performed a large, pooled analysis to further define and explore the role of circulating tumor cell count as a tool for early treatment monitoring in patients with metastatic breast cancer (MBC).
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
